Diovan

Selected form

Valsartan

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Hypotensive

Treatment option: Hypertension, Hypertension In Children

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diovan

Defining Diovan: What Type of Medicine Is It?

This section provides a factual overview of the identity, composition, and general purpose of the medication Diovan, focusing exclusively on its classification and essential characteristics.

Property	Description
Active ingredient	Valsartan
Form	Film-coated tablet (oral solution also available)
Pharmacological class	Angiotensin II Receptor Blocker (ARB) / Antihypertensive Agent
Common use	Management of high blood pressure and certain cardiovascular conditions
Origin	Synthetic, nonpeptide compound

Diovan: Classification and Composition

Diovan is the original trade name for the active ingredient Valsartan, a synthetic compound developed by Novartis and classified as a prescription-only medication (Rx). It belongs to the pharmacological class known as Angiotensin II receptor blockers (ARBs), which are clinically recognized for their use as primary antihypertensive agents. Valsartan is a nonpeptide molecule and is delivered primarily as an oral, film-coated tablet, a form engineered to ensure consistent systemic absorption. The formulation is typically a single-entity product, containing only Valsartan, though it is also notably available in co-formulations with other cardiovascular agents.

Valsartan: General Purpose and Physiological Role

The general purpose of Valsartan is to support long-term cardiovascular stability by promoting the relaxation of blood vessels and assisting the body in maintaining proper fluid balance. This effect is centered on selective Angiotensin II receptor blockade, where Valsartan inhibits the action of the hormone Angiotensin II, which otherwise causes blood vessels to constrict and narrow. By blocking this primary constricting action, the medication allows the blood vessels to widen, which reduces peripheral resistance and lessens the workload on the heart. This capability is particularly relevant in the consistent management of high blood pressure, where effective control is necessary to mitigate long-term cardiovascular risk.

Regulatory References

Angiotensin II Receptor Blockers (ARBs)

What side effects are possible with Diovan?

Possible Side Effects and Safety Information

Diovan (valsartan) has a documented safety profile established in clinical trials and postmarketing reports. Adverse reactions are classified by frequency and the System-Organ Class (SOC) affected, following regulatory standards.

Commonly Documented Adverse Reactions

Adverse effects listed as common in official regulatory documents often include: dizziness, headache, fatigue, hyperkalemia (increased potassium levels), and hypotension (low blood pressure). Effects involving the body's systems include diarrhea or abdominal pain (Gastrointestinal) and back pain or arthralgia (Musculoskeletal).

Serious Adverse Reactions and Constraints

The most serious documented safety risk is Fetal Toxicity: use during the second and third trimesters of pregnancy can cause injury and death to the developing fetus, and is a strong restriction noted in the labeling. Postmarketing reports also cite serious adverse reactions such as angioedema (swelling of the face, lips, or throat), renal failure, and hepatic function abnormalities.

Population and Exposure-Specific Safety Notes

Safety notes specify caution for certain patient populations. Symptomatic hypotension is noted as more likely to occur at the initiation of therapy, particularly in patients who are volume- or salt-depleted. Patients with impaired renal function or severe hepatic impairment require specific consideration, as adverse reactions like hyperkalemia are more likely in the context of reduced kidney function. The medication is also contraindicated in individuals with a known hypersensitivity to the product.

Overdose and Emergency Response

Overdose Manifestations and Immediate Actions

Overdosage of Diovan (Valsartan) is officially documented to result in manifestations consistent with the drug’s primary blood pressure-lowering action. The most frequently reported clinical presentation is hypotension (severely low blood pressure). Other documented physiological signs of overexposure include cardiac rate disturbances, such as tachycardia (abnormally fast heart rate) or, less commonly, bradycardia (abnormally slow heart rate). More severe outcomes documented in regulatory sources include circulatory collapse, shock, and an altered or depressed level of consciousness.

Immediate medical attention must be sought for any suspected overdose event or when severe clinical signs, such as symptomatic hypotension, depressed consciousness, circulatory collapse, or shock, are present. These severe manifestations define the urgent need for emergency care.

Regulatory-Documented Management and Constraints

The official profile mandates supportive treatment to manage the patient's symptoms. For individuals experiencing symptomatic hypotension, the procedural instructions include placing the patient in the supine position and, if determined necessary by healthcare providers, administering an intravenous (i.v.) infusion of normal saline to help stabilize systemic blood pressure.

The regulatory documentation explicitly confirms that no specific antidote is known for Valsartan overexposure. Additionally, it is noted that the active substance is not removed from the plasma by hemodialysis, a critical constraint for procedural management options. No specific differential overdose manifestations are defined in the regulatory labeling for particular patient populations.

Therapeutic Uses of Diovan

Diovan (valsartan) is an angiotensin II receptor blocker (ARB) commonly used across therapeutic domains where additional symptomatic support is needed for managing serious cardiovascular health issues. The medication is commonly used to help with three core categories of conditions: hypertension (high blood pressure), heart failure, and conditions associated with acute or disruptive episodes like a recent myocardial infarction (heart attack).

Its use is relevant for easing symptoms related to heightened physiological activity, particularly the elevated pressure linked to hypertension. In clinical settings, it is considered relevant often used during phases when symptoms become more noticeable. In scenarios involving recurrent or episodic manifestations like heart failure, valsartan assists with maintaining functional stability and managing symptoms related to systemic imbalance.

In essence, the drug provides supportive relief when symptoms interfere with routine activities. The patient benefit may be part of symptomatic management that contributes to easing the overall symptom load.

Quick Fact: Applied in addressing symptoms related to heightened physiological activity

Eligibility and Restrictions for Use

Eligibility Scope: Official Regulatory Information

The population eligibility for Diovan (valsartan) is defined by patient age, physiological state, and co-existing health conditions, as documented in official government labeling.

Populations for Whom Use is Approved:

Adults: Approved for all labeled indications (hypertension, heart failure, post-myocardial infarction).
Pediatric Patients: Approved for treating hypertension only in children generally aged ge 6 years (some labels specify ge 1 year).
Older Adults: No initial dose adjustment is typically required.

Absolute Contraindications (Must Not Use):

Pregnancy: Contraindicated during the second and third trimesters due to risk of fetal injury.
Hypersensitivity: Known sensitivity to valsartan or any component of the formulation.
Severe Hepatic Conditions: Severe hepatic impairment, biliary cirrhosis, or cholestasis.
Dual RAS Blockade: Concomitant use with aliskiren in patients with Diabetes Mellitus or moderate-to-severe renal impairment.

Eligibility-Related Restrictions: Use is not recommended for children below the minimum approved age or for pediatric patients requiring treatment for heart failure. Caution is required in patients with severe renal impairment (creatinine clearance < 10 mL/min), volume depletion, or unilateral/bilateral renal artery stenosis. Use is also not recommended during the first trimester of pregnancy or while breastfeeding.

What should I know about interactions with other medicines?

The interaction profile for Diovan (valsartan) is defined by pharmacodynamic effects on cardiovascular homeostasis and specific alterations to drug exposure, all as documented in official regulatory sources. Co-administration of valsartan with aliskiren is formally contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment, representing a dual blockade of the renin-angiotensin system (RAS).

Interacting Substance/Class	Official Interaction Outcome	Mechanism Classification
Agents Increasing Serum Potassium	Increases the risk of hyperkalemia and may increase serum creatinine.	Pharmacodynamic Reinforcement
NSAIDs and COX-2 Inhibitors	Increases the risk of renal impairment and may cause a loss of antihypertensive effect.	Pharmacodynamic
Lithium	Increases serum lithium concentrations and the risk of lithium toxicity by decreasing its clearance.	Pharmacodynamic

Use of valsartan with other RAS inhibitors (like ACE inhibitors) also increases the risk of hypotension, hyperkalemia, and changes in renal function. Separately, valsartan is a substrate for hepatic uptake transporters. Co-administration with inhibitors of these transporters, such as rifampin or ritonavir, officially increases the systemic exposure and peak concentration of valsartan. While the risk of renal impairment with NSAIDs is noted to be greater in the elderly or those with compromised renal function, valsartan may be administered with or without food.

Mechanism of Action

Valsartan is an angiotensin II receptor blocker (ARB) and acts specifically as an antagonist of the angiotensin II type 1 (AT1) receptor. It blocks the binding of the endogenous hormone, angiotensin II, to the AT1 receptor, which is expressed primarily on vascular smooth muscle and various other tissues.

This interaction inhibits the receptor-mediated signaling cascade, preventing the AT1-dependent effects of angiotensin II, which include vasoconstriction. The downstream physiological consequence of this blockade is a reduced peripheral vascular resistance and decreased systemic vascular tone. Inhibition of the AT1 receptor also influences myocardial contractility and systemic perfusion, and may modulate profibrotic and inflammatory pathways in renal and vascular tissues.

Dosage and Administration Information

How Diovan (Valsartan) is Used in Clinical Practice

The usage of Diovan is governed by specific administration principles. Valsartan is administered by the oral route only, primarily in the form of film-coated tablets, although an oral suspension can be prepared for certain administration needs. The medication can be taken with or without food, offering flexibility in scheduling the daily dose.

Dosing Frequency and Titration

Administration frequency is determined by the condition being managed. For hypertension, the medicine is typically administered once daily. For the management of heart failure and conditions following a myocardial infarction, the medicine is administered in divided doses, twice daily.

Treatment begins with a starting dose, followed by titration (stepwise dose adjustment) over a period of weeks, based on the clinical response, aiming for a maximal tolerated long-term dose. The full antihypertensive effect is typically achieved after approximately four weeks of sustained use.

Standard Dosing Ranges

Indication	Starting Dose Range	Maximum Total Daily Dose
Hypertension	80 mg to 160 mg once daily	320 mg
Heart Failure/Post-MI	20 mg to 40 mg twice daily	320 mg

Population-Specific Use

Dosage may be adjusted for specific patient groups. For pediatric patients (6–16 years) with hypertension, dosing is calculated based on body weight. No initial dosage adjustment is typically required for older adults or those with mild to moderate renal or hepatic impairment. If a dose is missed, it should be taken as soon as possible, unless it is close to the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence: Overview of Valsartan Studies

This section provides a summary of the official clinical research that has examined the active ingredient valsartan (Diovan), detailing the types of studies conducted and what the findings indicate, strictly without offering any medical or clinical advice.

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research examining valsartan for high blood pressure primarily involves large, long-term Randomized Controlled Trials (RCTs). The primary focus of these trials was to monitor blood pressure levels, specifically the Systolic and Diastolic Blood Pressure (SBP/DBP), over short periods. The largest studies extended the follow-up duration to track major cardiovascular events, such as the rates of stroke, non-fatal heart attack, and cardiovascular death.

Data show patterns related to measured changes in blood pressure, which is consistent across many trials. Findings describe patterns observed in the studies related to how the drug was observed when compared against other non-ARB agents.

What remains unclear is the extent of any specific pattern observed beyond its effects on lowering blood pressure alone. Data for certain groups remain insufficient regarding very long-term outcomes extending beyond five years.

Evidence for Use in Chronic Heart Failure

For heart failure, the evidence is founded on large-scale, event-driven Randomized Controlled Trials. Valsartan was evaluated in patients with symptomatic chronic heart failure, often used in addition to other standard heart failure medications. Researchers primarily monitored all-cause death, cardiovascular death, and the frequency of hospitalization for heart failure, along with changes in functional status. Studies also monitored patient-reported outcomes describing perceived discomfort.

Findings from these studies described patterns in the measured rate of hospitalization for heart failure between the observed groups. However, when researchers examined the overall mortality endpoint in the total study population, the findings were mixed. Follow-up durations were limited in some contexts, meaning longer-term data is not always available.

Evidence for Effects on Kidney Health (Diabetic Nephropathy)

Valsartan was studied for its application in patients with kidney issues, particularly those with Type 2 Diabetes Mellitus who had microalbuminuria (protein in the urine). These studies examined outcomes related to physiological strain or stress by monitoring the amount of protein being excreted in the urine. This marker was monitored in the studies.

Research provides insight into short-term changes and described patterns related to measured changes in the level of these biomarkers. Much of the data on preventing progression to End-Stage Kidney Disease (ESKD) is derived from secondary analyses of larger cardiovascular studies rather than dedicated primary trials, meaning certainty remains low regarding this specific long-term outcome.

Research Gaps and Limitations

The research mainly focused on high-risk populations; therefore, results apply only to the populations studied. The long-term measured patterns of valsartan on cardiovascular event reduction in the pediatric population are not fully established. Across all areas, comparative evidence is lacking when trying to assess valsartan against some of the newest treatment options that have emerged since the original landmark trials were conducted.

Frequently Asked Questions (FAQ)

Common questions about Diovan (FAQ)

Q: Is Diovan a type of beta-blocker?

A: No, Diovan (valsartan) is not a beta-blocker. Official regulatory information classifies it as an Angiotensin II Receptor Blocker (ARB). These two drug classes work in different ways to help manage blood pressure, although they may sometimes be used together in combination therapies.

Q: What is the difference between Diovan and Lisinopril?

A: Diovan (valsartan) is an ARB, which works by directly blocking the action of the hormone Angiotensin II. Lisinopril belongs to a different class called ACE inhibitors, which work by preventing the body from creating Angiotensin II. Both classes are used for blood pressure management but have distinct mechanisms of action.

Q: Can Diovan affect kidney function over time?

A: Official product information indicates that valsartan use may be associated with changes in kidney function, including the risk of renal impairment or renal failure in some individuals. Monitoring of kidney function with blood tests may be performed by your healthcare provider during treatment, as is common with this class of medication.

Q: Do headaches go away after adjusting to Diovan?

A: Headache is listed as a commonly reported side effect of Diovan in clinical trials. While product information does not give a specific timeline, many common side effects often lessen or resolve as the body adjusts to a new medication. If headaches persist, it is appropriate to consult your healthcare provider.

Q: Can people with diabetes safely take Diovan?

A: Valsartan is approved for the treatment of certain kidney issues in patients with Type 2 Diabetes Mellitus. However, a specific restriction noted in regulatory documents is that Diovan is contraindicated (must not be used) in combination with the drug aliskiren in patients who also have diabetes.

Q: Does Diovan help protect against stroke?

A: Diovan is approved for the management of high blood pressure, which is a primary risk factor for stroke. Clinical studies monitor for major cardiovascular events, including stroke, but the primary labeled indication is blood pressure lowering.

Q: Can Diovan cause a persistent cough?

A: A cough has been reported as an adverse reaction in clinical trials involving valsartan, according to regulatory data. While a persistent cough is more typically associated with ACE inhibitors (a related drug class), it is an effect that can potentially occur with Diovan as well.

Q: Can I take multivitamins while on Diovan?

A: Regulatory documents indicate a need for caution with potassium supplements or salt substitutes containing potassium, as taking them with valsartan can increase potassium levels in the blood. For multivitamins, it is advisable to check the ingredients for any added potassium.

Q: Can I take cold and flu medicine while taking Diovan?

A: Many cold and flu medicines contain ingredients that may interact with Diovan. These can include NSAIDs (like ibuprofen) or certain decongestants. NSAIDs may increase the risk of kidney problems and reduce the blood pressure-lowering effect of valsartan. Consulting with a healthcare professional regarding all over-the-counter products, including cold and flu medicines, is recommended.

Q: Are there any studies on Diovan's use in children?

A: Yes, official regulatory labeling includes data from studies regarding the treatment of hypertension in pediatric patients. This research has resulted in the approval of valsartan for use in children generally aged 6 to 16 years, with specific dosing determined by body weight.

Q: Can Diovan be split or crushed if I have trouble swallowing pills?

A: Diovan is typically supplied as a film-coated tablet. Official labeling mentions that an oral suspension can be specially prepared for certain administration needs. Generally, film-coated tablets are not intended to be split or crushed, and consultation with a healthcare provider is recommended before altering the tablet form.

Q: What is the connection between Diovan and potassium levels?

A: Valsartan's mechanism of action can affect the body's system for regulating salt and water balance, which can lead to increased potassium in the blood, a condition called hyperkalemia. This condition is noted as an adverse reaction in official product information, and potassium levels may be monitored during treatment.

Q: Is Diovan commonly used after a heart attack?

A: Yes, valsartan is formally indicated (approved for use) to help reduce the risk of cardiovascular death in clinically stable patients with left ventricular dysfunction following a heart attack (myocardial infarction).

Q: Are there any long-term effects of taking Diovan for many years?

A: Valsartan is intended for the long-term management of chronic conditions. While regulatory documents note that long-term clinical trials have been conducted, information regarding outcomes for treatment extending beyond the scope of those trials is not fully established.

Q: What is the success rate of Diovan in managing hypertension?

A: Official clinical trial data show that valsartan produces a significant blood pressure-lowering effect, usually within two weeks, with the maximum effect generally seen after approximately four weeks of consistent use. The regulatory label describes the magnitude of blood pressure reduction rather than a single 'success rate' percentage.

Q: How often do blood tests need to be done when taking Diovan?

A: Official product information advises that blood tests may be performed to check your potassium levels and kidney function (creatinine) as deemed necessary by the prescriber. The precise frequency for monitoring is determined by the prescriber based on clinical assessment.

Q: Is it normal to feel tired or fatigued on Diovan?

A: Fatigue (tiredness) is listed as a commonly documented adverse reaction in official product information based on clinical trial data. If fatigue is persistent or concerning, consultation with a healthcare provider is appropriate.

How should Diovan be stored and disposed of?

Diovan (valsartan) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication must be kept in the container it came in, with the lid tightly closed, in a cool, dry place to protect it from excessive heat and moisture. All forms of valsartan must be stored out of the sight and reach of children.

For the oral liquid suspension, stability is dependent on temperature: it is stable for up to 30 days at room temperature or up to 75 days if refrigerated.

Unused or expired product should be disposed of according to official pharmaceutical waste handling instructions. The medicine should not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.